Beauty Health Analyst Ratings
Beauty Health Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/25/2023 | 64.47% | Canaccord Genuity | → $10 | Assumes | → Buy |
| 08/10/2023 | 48.03% | TD Cowen | $15 → $9 | Maintains | Outperform |
| 08/10/2023 | 171.38% | DA Davidson | $35 → $16.5 | Maintains | Buy |
| 08/08/2023 | 278.29% | Benchmark | → $23 | Reiterates | Buy → Buy |
| 06/21/2023 | 64.47% | Stifel | $17 → $10 | Downgrades | Buy → Hold |
| 05/26/2023 | 97.37% | JP Morgan | $13 → $12 | Maintains | Neutral |
| 05/18/2023 | 278.29% | Benchmark | → $23 | Reiterates | Buy → Buy |
| 05/11/2023 | 475.66% | DA Davidson | → $35 | Reiterates | → Buy |
| 03/28/2023 | 196.05% | Canaccord Genuity | → $18 | Reiterates | → Buy |
| 03/20/2023 | — | Exane BNP Paribas | Upgrades | Underperform → Neutral | |
| 03/14/2023 | 278.29% | Benchmark | → $23 | Reiterates | → Buy |
| 03/01/2023 | 475.66% | DA Davidson | $32 → $35 | Maintains | Buy |
| 02/28/2023 | 278.29% | Benchmark | → $23 | Reiterates | → Buy |
| 02/16/2023 | 146.71% | Cowen & Co. | $20 → $15 | Maintains | Outperform |
| 11/23/2022 | 212.5% | Goldman Sachs | $22 → $19 | Maintains | Buy |
| 11/09/2022 | 80.92% | JP Morgan | $22 → $11 | Downgrades | Overweight → Neutral |
| 11/09/2022 | 426.32% | DA Davidson | $31 → $32 | Maintains | Buy |
| 09/28/2022 | 409.87% | DA Davidson | $30 → $31 | Maintains | Buy |
| 09/16/2022 | 278.29% | Piper Sandler | $20 → $23 | Maintains | Overweight |
| 09/16/2022 | 393.42% | DA Davidson | $25 → $30 | Maintains | Buy |
| 08/16/2022 | 261.84% | Goldman Sachs | $25 → $22 | Maintains | Buy |
| 08/10/2022 | 228.95% | Piper Sandler | $22 → $20 | Maintains | Overweight |
| 08/10/2022 | 311.18% | DA Davidson | $24 → $25 | Maintains | Buy |
| 07/08/2022 | 261.84% | Piper Sandler | $24 → $22 | Maintains | Overweight |
| 06/30/2022 | 228.95% | Canaccord Genuity | $22 → $20 | Maintains | Buy |
| 05/12/2022 | 294.74% | DA Davidson | $35 → $24 | Maintains | Buy |
| 05/11/2022 | 311.18% | Goldman Sachs | $29 → $25 | Maintains | Buy |
| 05/11/2022 | 294.74% | Piper Sandler | $26 → $24 | Maintains | Overweight |
| 04/28/2022 | 327.63% | Piper Sandler | $31 → $26 | Maintains | Overweight |
| 03/14/2022 | 278.29% | Benchmark | $18 → $23 | Maintains | Buy |
| 03/11/2022 | 294.74% | JP Morgan | → $24 | Initiates Coverage On | → Overweight |
| 02/23/2022 | 475.66% | DA Davidson | $32 → $35 | Maintains | Buy |
| 01/07/2022 | — | William Blair | Initiates Coverage On | → Outperform | |
| 12/23/2021 | — | Raymond James | Initiates Coverage On | → Market Perform | |
| 11/10/2021 | 426.32% | DA Davidson | $26 → $32 | Maintains | Buy |
| 10/08/2021 | 442.76% | Stifel | → $33 | Initiates Coverage On | → Buy |
| 10/04/2021 | 426.32% | Cowen & Co. | → $32 | Initiates Coverage On | → Outperform |
| 08/11/2021 | 327.63% | DA Davidson | $17.5 → $26 | Maintains | Buy |
| 07/19/2021 | 261.84% | Jefferies | → $22 | Initiates Coverage On | → Buy |
| 07/01/2021 | 409.87% | Goldman Sachs | → $31 | Initiates Coverage On | → Buy |
| 06/24/2021 | 294.74% | Piper Sandler | → $24 | Initiates Coverage On | → Overweight |
| 06/15/2021 | 245.39% | Canaccord Genuity | → $21 | Initiates Coverage On | → Buy |
| 06/01/2021 | 187.83% | DA Davidson | $16 → $17.5 | Maintains | Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 08/25/2023 | 64.47% | Canaccord Genu | → 10 美元 | 假設 | → 購買 |
| 08/10/2023 | 48.03% | TD Cowen | 15 美元 → 9 美元 | 維護 | 跑贏大盤 |
| 08/10/2023 | 171.38% | DA Davidson | 35 美元 → 16.5 美元 | 維護 | 購買 |
| 08/08/2023 | 278.29% | 基準 | → 23 美元 | 重申 | 購買 → 購買 |
| 06/21/2023 | 64.47% | Stifel | 17 美元 → 10 美元 | 降級 | 買入 → 持有 |
| 05/26/2023 | 97.37% | 摩根大通 | 13 美元 → 12 美元 | 維護 | 中立 |
| 05/18/2023 | 278.29% | 基準 | → 23 美元 | 重申 | 購買 → 購買 |
| 05/11/2023 | 475.66% | DA Davidson | → 35 美元 | 重申 | → 購買 |
| 03/28/2023 | 196.05% | Canaccord Genu | → 18 美元 | 重申 | → 購買 |
| 03/20/2023 | — | Exane BNP Paribas | 升級 | 表現不佳 → 中性 | |
| 03/14/2023 | 278.29% | 基準 | → 23 美元 | 重申 | → 購買 |
| 03/01/2023 | 475.66% | DA Davidson | 32 美元 → 35 美元 | 維護 | 購買 |
| 02/28/2023 | 278.29% | 基準 | → 23 美元 | 重申 | → 購買 |
| 02/16/2023 | 146.71% | Cowen & Co. | 20 美元 → 15 美元 | 維護 | 跑贏大盤 |
| 2022 年 11 月 23 日 | 212.5% | 高盛 | 22 美元 → 19 美元 | 維護 | 購買 |
| 11/09/2022 | 80.92% | 摩根大通 | 22 美元 → 11 美元 | 降級 | 超重 → 中性 |
| 11/09/2022 | 426.32% | DA Davidson | 31 美元 → 32 美元 | 維護 | 購買 |
| 2022 年 9 月 28 日 | 409.87% | DA Davidson | 30 美元 → 31 美元 | 維護 | 購買 |
| 2022 年 9 月 16 日 | 278.29% | 派珀·桑德勒 | 20 美元 → 23 美元 | 維護 | 超重 |
| 2022 年 9 月 16 日 | 393.42% | DA Davidson | 25 美元 → 30 美元 | 維護 | 購買 |
| 08/16/2022 | 261.84% | 高盛 | 25 美元 → 22 美元 | 維護 | 購買 |
| 08/10/2022 | 228.95% | 派珀·桑德勒 | 22 美元 → 20 美元 | 維護 | 超重 |
| 08/10/2022 | 311.18% | DA Davidson | 24 美元 → 25 美元 | 維護 | 購買 |
| 07/08/2022 | 261.84% | 派珀·桑德勒 | 24 美元 → 22 美元 | 維護 | 超重 |
| 06/30/2022 | 228.95% | Canaccord Genu | 22 美元 → 20 美元 | 維護 | 購買 |
| 2022 年 12 月 5 日 | 294.74% | DA Davidson | 35 美元 → 24 美元 | 維護 | 購買 |
| 05/11/2022 | 311.18% | 高盛 | 29 美元 → 25 美元 | 維護 | 購買 |
| 05/11/2022 | 294.74% | 派珀·桑德勒 | 26 美元 → 24 美元 | 維護 | 超重 |
| 04/28/2022 | 327.63% | 派珀·桑德勒 | 31 美元 → 26 美元 | 維護 | 超重 |
| 03/14/2022 | 278.29% | 基準 | 18 美元 → 23 美元 | 維護 | 購買 |
| 03/11/2022 | 294.74% | 摩根大通 | → 24 美元 | 啓動覆蓋開啓 | → 超重 |
| 2022 年 2 月 23 日 | 475.66% | DA Davidson | 32 美元 → 35 美元 | 維護 | 購買 |
| 2022 年 7 月 1 日 | — | 威廉布萊爾 | 啓動覆蓋開啓 | → 跑贏大盤 | |
| 12/23/2021 | — | 雷蒙德·詹姆 | 啓動覆蓋開啓 | → 市場表現 | |
| 11/10/2021 | 426.32% | DA Davidson | 26 美元 → 32 美元 | 維護 | 購買 |
| 2021 年 8 月 10 日 | 442.76% | Stifel | → 33 美元 | 啓動覆蓋開啓 | → 購買 |
| 2021 年 4 月 10 日 | 426.32% | Cowen & Co. | → 32 美元 | 啓動覆蓋開啓 | → 跑贏大盤 |
| 08/11/2021 | 327.63% | DA Davidson | 17.5 美元 → 26 美元 | 維護 | 購買 |
| 07/19/2021 | 261.84% | 傑富瑞 | → 22 美元 | 啓動覆蓋開啓 | → 購買 |
| 07/01/2021 | 409.87% | 高盛 | → 31 美元 | 啓動覆蓋開啓 | → 購買 |
| 2021 年 6 月 24 日 | 294.74% | 派珀·桑德勒 | → 24 美元 | 啓動覆蓋開啓 | → 超重 |
| 06/15/2021 | 245.39% | Canaccord Genu | → 21 美元 | 啓動覆蓋開啓 | → 購買 |
| 06/01/2021 | 187.83% | DA Davidson | 16 美元 → 17.5 美元 | 維護 | 購買 |
What is the target price for Beauty Health (SKIN)?
Beauty Health（SKIN）的目標價格是多少？
The latest price target for Beauty Health (NASDAQ: SKIN) was reported by Canaccord Genuity on August 25, 2023. The analyst firm set a price target for $10.00 expecting SKIN to rise to within 12 months (a possible 64.47% upside). 20 analyst firms have reported ratings in the last year.
Canaccord Genuity於2023年8月25日公佈了Beauty Health（納斯達克股票代碼：SKIN）的最新目標股價。該分析公司將目標股價定爲10.00美元，預計SKIN將在12個月內上漲至64.47％（可能上漲64.47％）。去年有20家分析公司公佈了評級。
What is the most recent analyst rating for Beauty Health (SKIN)?
分析師對美容健康（SKIN）的最新評級是多少？
The latest analyst rating for Beauty Health (NASDAQ: SKIN) was provided by Canaccord Genuity, and Beauty Health their buy rating.
美容健康（納斯達克股票代碼：SKIN）的最新分析師評級由Canaccord Genuity提供，Beauty Health爲買入評級。
When is the next analyst rating going to be posted or updated for Beauty Health (SKIN)?
Beauty Health（SKIN）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Beauty Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Beauty Health was filed on August 25, 2023 so you should expect the next rating to be made available sometime around August 25, 2024.
分析師在進行了廣泛的研究後得出了股票評級，包括閱讀公開財務報表、與Beauty Health的高管和客戶交談以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。Beauty Health的最新評級是在2023年8月25日提交的，因此你應該預計下一個評級將在2024年8月25日左右公佈。
Is the Analyst Rating Beauty Health (SKIN) correct?
分析師對美容健康 (SKIN) 的評級是否正確？
While ratings are subjective and will change, the latest Beauty Health (SKIN) rating was a with a price target of $0.00 to $10.00. The current price Beauty Health (SKIN) is trading at is $6.08, which is within the analyst's predicted range.
雖然評級是主觀的，並且會發生變化，但最新的Beauty Health（SKIN）評級爲目標價爲0.00美元至10.00美元。Beauty Health（SKIN）的當前交易價格爲6.08美元，在分析師的預測區間內。
譯文內容由第三人軟體翻譯。